[en] Background: We analysed kinetics of IL-7 and IL-15 levels in 70 patients given peripheral blood stem cells after
nonmyeloablative conditioning.
Methods: EDTA-anticoagulated plasma and serum samples were obtained before conditioning and about once per week after transplantation until day 100. Samples were aliquoted and stored at 280uC within 3 hours after collection until measurement of cytokines. IL-7 and IL-15 levels were measured by ELISAs.
Results: Median IL-7 plasma levels remained below 6 pg/L throughout the first 100 days, although IL-7 plasma levels were significantly higher on days 7 (5.1 pg/mL, P = 0.002), 14 (5.2 pg/mL, P,0.001), and 28 (5.1 pg/mL, P = 0.03) (but not thereafter) than before transplantation (median value of 3.8 pg/mL). Median IL-15 serum levels were significantly higher on days 7 (12.5 pg/mL, P,0.001), 14 (10.5 pg/mL, P,0.001), and 28 (6.2 pg/mL, P,0.001) than before transplantation (median value of 2.4 pg/mL). Importantly, IL-7 and IL-15 levels on days 7 or 14 after transplantation did not predict grade II–IV acute GVHD.
Conclusions: These data suggest that IL-7 and IL-15 levels remain relatively low after nonmyeloablative transplantation, and that IL-7 and IL-15 levels early after nonmyeloablative transplantation do not predict for acute GVHD.
Disciplines :
Hematology
Author, co-author :
De Bock, Muriel
Fillet, Marianne ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, et al. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068-1073.
Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, et al. (2010) NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant 16: 565-586.
Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, et al. (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23: 1993-2003.
Baron F, Petersdorf EW, Gooley T, Sandmaier BM, Malkki M, et al. (2009) What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 15: 580-588.
Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, et al. (2012) Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 26: 2462-2468.
Crooks GM, Weinberg K, Mackall C, (2006) Immune reconstitution: from stem cells to lymphocytes. Biol Blood Marrow Transplant 12: 42-46.
Peggs KS, (2006) Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans. Cytotherapy 8: 427-436.
Gress RE, Emerson SG, Drobyski WR, (2010) Immune reconstitution: how it should work, what's broken, and why it matters. Biol Blood Marrow Transplant 16: S133-S137.
Clave E, Busson M, Douay C, Peffault de Latour R, Berrou J, et al. (2009) Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 113: 6477-6484.
Bahceci E, Epperson D, Douek DC, Melenhorst JJ, Childs RC, et al. (2003) Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. Br J Haematol 122: 934-943.
Fallen PR, McGreavey L, Madrigal JA, Potter M, Ethell M, et al. (2003) Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 32: 1001-1014.
Toubert A, Glauzy S, Douay C, Clave E, (2012) Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens 79: 83-89 doi:10.1111/j.1399-0039.2011.01820.x.
Bosch M, Khan FM, Storek J, (2012) Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 19: 324-335 doi:10.1097/MOH.0b013e328353bc7d.
Federmann B, Hagele M, Pfeiffer M, Wirths S, Schumm M, et al. (2011) Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 25: 121-129 doi:10.1038/leu.2010.235.
Storek J, Dawson MA, Maloney DG, (2003) Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation. Biol Blood Marrow Transplant 9: 781-784.
Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, et al. (2000) Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 355: 1875-1881.
Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, et al. (2001) Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97: 1458-1466.
Hochberg EP, Chillemi AC, Wu CJ, Neuberg D, Canning C, et al. (2001) Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood 98: 1116-1121.
Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, et al. (2002) Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 100: 2235-2242.
Hazenberg MD, Otto SA, de Pauw ES, Roelofs H, Fibbe WE, et al. (2002) T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood 99: 3449-3453.
Krenger W, Blazar BR, Hollander GA, (2011) Thymic T-cell development in allogeneic stem cell transplantation. Blood 117: 6768-6776.
Mackall CL, Fry TJ, Gress RE, (2011) Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 11: 330-342.
Puel A, Ziegler SF, Buckley RH, Leonard WJ, (1998) Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 20: 394-397.
Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, et al. (2001) IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 97: 1491-1497.
Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, et al. (2001) Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98: 2256-2265.
Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, et al. (2003) IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 101: 2294-2299.
Chu YW, Memon SA, Sharrow SO, Hakim FT, Eckhaus M, et al. (2004) Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 104: 1110-1119.
Storek J, Gillespy TI, Lu H, Joseph A, Dawson MA, et al. (2003) Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 101: 4209-4218.
Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, et al. (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205: 1701-1714.
Beq S, Nugeyre MT, Ho Tsong FR, Gautier D, Legrand R, et al. (2006) IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 176: 914-922.
Fehniger TA, Caligiuri MA, (2001) Interleukin 15: biology and relevance to human disease (Review). Blood 97: 14-32.
Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, et al. (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.
Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, et al. (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195: 1523-1532.
Goldrath AW, Sivakumar PV, Glaccum M, Kennedy MK, Bevan MJ, et al. (2002) Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 195: 1515-1522.
Berard M, Brandt K, Bulfone-Paus S, Tough DF, (2003) IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol 170: 5018-5026.
Alves NL, Hooibrink B, Arosa FA, van Lier RA, (2003) IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood 102: 2541-2546.
Alpdogan O, Eng JM, Muriglan SJ, Willis LM, Hubbard VM, et al. (2005) Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105: 865-873.
Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, et al. (2011) IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A 108: 6217-6222.
Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, et al. (2004) Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104: 2254-2262.
Baron F, Sandmaier BM, (2006) Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 20: 1690-1700.
Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, et al. (2010) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16: 838-847.
Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N, et al. (2008) Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 93: 240-247.
Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, et al. (2011) Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica 96: 298-306.
Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, et al. (2011) Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25: 498-505 doi:10.1038/leu.2010.283.
Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, et al. (2010) Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 45: 1546-1552 doi:10.1038/bmt.2010.13.
Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, et al. (1987) Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2: 175-178.
Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, et al. (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117: 6963-6970 doi:10.1182/blood-2011-01-332007.
Mohty M, Avinens O, Faucher C, Viens P, Blaise D, et al. (2007) Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 92: 1004-1006.
De Bock M, Fillet M, Merville MP, Gothot A, Beguin Y, et al. (2012) Kinetics of IL-7 and IL-15 Levels After Allogeneic Peripheral Blood Stem Cell Transplantation (allo-PBSCT) Following High-Dose or Nonmyeloablative Conditioning. Biol Blood Marrow Transplant 18suppl 2: s275.
Bolotin E, Annett G, Parkman R, Weinberg K, (1999) Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 23: 783-788.
Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, et al. (2011) Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 46: 1374-1381 doi:10.1038/bmt.2010.300.
Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, et al. (2008) Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol 26: 5735-5741 doi:10.1200/JCO.2008.17.1314.
Baron F, Schaaf-Lafontaine N, Humblet-Baron S, Meuris N, Castermans E, et al. (2003) T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation 76: 1705-1713.
Baron F, Storer B, Maris MB, Storek J, Piette F, et al. (2006) Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 12: 1176-1187.
Abu-Ghosh A, Goldman S, Slone V, van de Ven C, Suen Y, et al. (1999) Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant 24: 535-544 doi:10.1038/sj.bmt.1701921.
Hagel LM, Liu Y, Ugarte-Torres A, Williamson TS, Russell JA, et al. (2010) High IL-15 serum levels on day 7 after hematopoietic cell transplantation are associated with a low likelihood of graft-versus-host disease and a high likelihood of infections. ASH Annual Meeting Abstracts 116: 1271.
Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, et al. (2012) Recombinant human interleukin-7 (CYT107) promotes T cell recovery following allogeneic stem cell transplantation. Blood. doi:10.1182/blood-2012-06-437236.
Almawi WY, Assi JW, Chudzik DM, Jaoude MM, Rieder MJ, (2001) Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1. Cell Transplant 10: 615-623.
Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, et al. (2012) Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 18: 414-422 doi:10.1016/j.bbmt.2011.08.016.